Effects of peer education on depression, anxiety, stress?quality of life and adherence among patients receiving dialysis

Investigating the effects of peer education on depression, anxiety, stress?quality of life and adherence among patients receiving dialysis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171212037847N1

Enrollment

Registered

2018-06-30

Start date

2639-09-27

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease, stage 5. Chronic kidney disease, stage 5

Interventions

Intervention 1: Intervention group: peer education. Intervention 2: Control group: routine care services.

Eligibility

Sex/Gender

All

Age

1999 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients have definite diagnosis of renal failure, a history of receiving dialysis for more than three months no history of cognitive problems such as memory impairment no simultaneous participation in peer education programs

Exclusion criteria

Exclusion criteria: Recruited patients exclude if they voluntarily voluntarily chose to withdraw from the study patients exclude if they incompletely filled out study questionnaire patients exclude if they hospitalize in hospital patients exclude if they underwent kidney transplant surgery during the study.

Design outcomes

Primary

Measure	Time frame
Depression. Timepoint: Patients’ depression assess before and immediately and 1 month after the intervention via the 42-item Depression Anxiety Stress Scale (DASS-42). Method of measurement: Patients’ depression assess via the depression Anxiety Stress Scale -42 Item(DASS- 42).;Anxiety. Timepoint: Patients’ anxiety assess before and immediately and 1 month after the intervention via the 42-item Depression Anxiety Stress Scale (DASS-42). Method of measurement: Patients’ anxiety assess via the depression Anxiety Stress Scale -42 Item(DASS- 42).;Stress. Timepoint: Patients’ stress assess before and immediately and 1 month after the intervention via the 42-item Depression Anxiety Stress Scale (DASS-42). Method of measurement: Patients’ stress assess via the depression Anxiety Stress Scale -42 Item(DASS- 42).;Quality of life. Timepoint: Patients’ quality of life assess before and immediately after the intervention via the Kidney Disease Quality of Life–Short Form version 1.3 (KDQOL-SF ver. 1.3). Method of measurement: Patients’ quality of life assess via the Kidney Disease Quality of Life–Short Form version 1.3 (KDQOL-SF ver. 1.3).;Adherence. Timepoint: Patients’ adherence assess before and immediately after the intervention via the end-Stage Renal Disease Adherence Questionnaire (ESRDAQ). Method of measurement: Patients’ adherence assess via the end-Stage Renal Disease Adherence Questionnaire (ESRDAQ).	—

Measure

Time frame

Depression. Timepoint: Patients’ depression assess before and immediately and 1 month after the intervention via the 42-item Depression Anxiety Stress Scale (DASS-42). Method of measurement: Patients’ depression assess via the depression Anxiety Stress Scale -42 Item(DASS- 42).;Anxiety. Timepoint: Patients’ anxiety assess before and immediately and 1 month after the intervention via the 42-item Depression Anxiety Stress Scale (DASS-42). Method of measurement: Patients’ anxiety assess via the depression Anxiety Stress Scale -42 Item(DASS- 42).;Stress. Timepoint: Patients’ stress assess before and immediately and 1 month after the intervention via the 42-item Depression Anxiety Stress Scale (DASS-42). Method of measurement: Patients’ stress assess via the depression Anxiety Stress Scale -42 Item(DASS- 42).;Quality of life. Timepoint: Patients’ quality of life assess before and immediately after the intervention via the Kidney Disease Quality of Life–Short Form version 1.3 (KDQOL-SF ver. 1.3). Method of measurement: Patients’ quality of life assess via the Kidney Disease Quality of Life–Short Form version 1.3 (KDQOL-SF ver. 1.3).;Adherence. Timepoint: Patients’ adherence assess before and immediately after the intervention via the end-Stage Renal Disease Adherence Questionnaire (ESRDAQ). Method of measurement: Patients’ adherence assess via the end-Stage Renal Disease Adherence Questionnaire (ESRDAQ).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Sadat Hashemi

Esfahan University of Medical Sciences

Maryamhashemi956@gmail.com+98 31 3225 3349

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026